Publication: Ampicillin Plus Ceftriaxone Combined Therapy for Enterococcus faecalis Infective Endocarditis in OPAT.
dc.contributor.author | Herrera-Hidalgo, Laura | |
dc.contributor.author | Lomas-Cabezas, Jose Manuel | |
dc.contributor.author | Lopez-Cortes, Luis Eduardo | |
dc.contributor.author | Luque-Marquez, Rafael | |
dc.contributor.author | Lopez-Cortes, Luis Fernando | |
dc.contributor.author | Martinez-Marcos, Francisco J | |
dc.contributor.author | de-la-Torre-Lima, Javier | |
dc.contributor.author | Plata-Ciezar, Antonio | |
dc.contributor.author | Hidalgo-Tenorio, Carmen | |
dc.contributor.author | Garcia-Lopez, Maria Victoria | |
dc.contributor.author | Vinuesa, David | |
dc.contributor.author | Gutierrez-Valencia, Alicia | |
dc.contributor.author | Gil-Navarro, Maria Victoria | |
dc.contributor.author | De-Alarcon, Aristides | |
dc.contributor.funder | Instituto de Salud Carlos III | |
dc.contributor.funder | European Regional Development Fund (“A way to achieve Europe”) | |
dc.date.accessioned | 2023-05-03T14:04:12Z | |
dc.date.available | 2023-05-03T14:04:12Z | |
dc.date.issued | 2021-12-21 | |
dc.description.abstract | Ampicillin plus ceftriaxone (AC) is a well-recognized inpatient regimen for Enterococcus faecalis infective endocarditis (IE). In this regimen, ceftriaxone is usually administered 2 g every 2 h (AC12). The administration of AC in outpatient parenteral antibiotic treatment (OPAT) programs is challenging because multiple daily doses are required. AC regimens useful for OPAT programs include once-daily high-dose administration of ceftriaxone (AC24) or AC co-diluted and jointly administered in bolus every 4 h (ACjoined). In this retrospective analysis of prospectively collected cases, we aimed to assess the clinical effectivity and safety of three AC regimens for the treatment of E. faecalis IE. Fifty-nine patients were treated with AC combinations (AC12 n = 32, AC24 n = 17, and ACjoined n = 10). Six relapses occurred in the whole cohort: five (29.4%) treated with AC24 regimen and one (10.0%) with ACjoined. Patients were cured in 30 (93.3%), 16 (94.1%), and eight (80.0%) cases in the AC12, AC24 and ACjoined groups, respectively. Unplanned readmission occurred in eight (25.0%), six (35.3%), and two (20.0%) patients in the AC12, AC24 and ACjoined groups, respectively. The outcome of patients with E. faecalis IE treated with AC in OPAT programs relies on an optimization of the delivery of the combination. AC24 exhibit an unexpected rate of failures, however, ACjoined might be an effective alternative which clinical results should corroborate in further studies. | |
dc.description.sponsorship | The authors received no financial support for the research, authorship, and/or publication of this article. GVA was supported by the Instituto de Salud Carlos III, cofinanced by the European Regional Development Fund (“A way to achieve Europe”), Subprograma Miguel Servet (grant CP19/00159). HHL was supported by the Instituto de Salud Carlos III, Subprograma Rio Hortega (grant CM19/00152). | |
dc.description.version | Si | |
dc.identifier.citation | Herrera-Hidalgo L, Lomas-Cabezas JM, López-Cortés LE, Luque-Márquez R, López-Cortés LF, Martínez-Marcos FJ, et al. Ampicillin Plus Ceftriaxone Combined Therapy for Enterococcus faecalis Infective Endocarditis in OPAT. J Clin Med. 2021 Dec 21;11(1):7 | |
dc.identifier.doi | 10.3390/jcm11010007 | |
dc.identifier.issn | 2077-0383 | |
dc.identifier.pmc | PMC8745305 | |
dc.identifier.pmid | 35011748 | |
dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745305/pdf | |
dc.identifier.unpaywallURL | https://www.mdpi.com/2077-0383/11/1/7/pdf?version=1640081737 | |
dc.identifier.uri | http://hdl.handle.net/10668/21221 | |
dc.issue.number | 1 | |
dc.journal.title | Journal of clinical medicine | |
dc.journal.titleabbreviation | J Clin Med | |
dc.language.iso | en | |
dc.organization | Hospital Universitario San Cecilio | |
dc.organization | Hospital Universitario Virgen de las Nieves | |
dc.organization | Hospital Universitario Juan Ramón Jiménez | |
dc.organization | Hospital Universitario Virgen de la Victoria | |
dc.organization | Hospital Costa del Sol | |
dc.organization | Hospital Universitario Regional de Málaga | |
dc.organization | Hospital Universitario Virgen del Rocío | |
dc.organization | Hospital Universitario Virgen Macarena | |
dc.organization | Instituto de Biomedicina de Sevilla-IBIS | |
dc.page.number | 8 | |
dc.provenance | Realizada la curación de contenido 10/03/2025 | |
dc.publisher | MDPI | |
dc.pubmedtype | Journal Article | |
dc.relation.projectID | CP19/00159 | |
dc.relation.projectID | CM19/00152 | |
dc.relation.publisherversion | https://www.mdpi.com/resolver?pii=jcm11010007 | |
dc.rights | Attribution 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Enterococcus faecalis | |
dc.subject | Ampicillin | |
dc.subject | Ceftriaxone | |
dc.subject | Infective endocarditis | |
dc.subject | Outpatient parenteral antibiotic treatment | |
dc.subject.decs | Ceftriaxona | |
dc.subject.decs | Organización y administración | |
dc.subject.decs | Recurrencia | |
dc.subject.decs | Pacientes internos | |
dc.subject.decs | Pacientes ambulatorios | |
dc.subject.decs | Ampicilina | |
dc.subject.mesh | Anti-Bacterial Agents | |
dc.subject.mesh | Ceftriaxone | |
dc.subject.mesh | Inpatients | |
dc.subject.mesh | Retrospective Studies | |
dc.subject.mesh | Patient Readmission | |
dc.subject.mesh | Ampicillin | |
dc.title | Ampicillin Plus Ceftriaxone Combined Therapy for Enterococcus faecalis Infective Endocarditis in OPAT. | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 11 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1